Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
J Neurol Neurosurg Psychiatry. 2024 Jan 11;95(2):134-141. doi: 10.1136/jnnp-2023-331784.
We analysed the COMparison Between All immunoTherapies for Multiple Sclerosis (NCT03193866), a Swedish nationwide observational study in relapsing-remitting multiple sclerosis (RRMS), to identify trajectories of processing speed and physical disability after disease-modulating therapy (DMT) start.
Using a group-modelling approach, we assessed trajectories of processing speed with oral Symbol Digit Modalities Test (SDMT) and physical disability with Expanded Disability Status Scale, from first DMT start among 1645 patients with RRMS followed during 2011-2022. We investigated predictors of trajectories using group membership as a multinomial outcome and calculated conditional probabilities linking membership across the trajectories.
We identified 5 stable trajectories of processing speed: low SDMT scores (mean starting values=29.9; 5.4% of population), low/medium (44.3; 25.3%), medium (52.6; 37.9%), medium/high (63.1; 25.8%) and high (72.4; 5.6%). We identified 3 physical disability trajectories: no disability/stable (0.8; 26.8%), minimal disability/stable (1.6; 58.1%) and moderate disability (3.2; 15.1%), which increased to severe disability. Older patients starting interferons were more likely than younger patients starting rituximab to be on low processing speed trajectories. Older patients starting teriflunomide, with more than one comorbidity, and a history of pain treatment were more likely to belong to the moderate/severe physical disability trajectory, relative to the no disability one. There was a strong association between processing speed and physical disability trajectories.
In this cohort of actively treated RRMS, patients' processing speed remained stable over the years following DMT start, whereas patients with moderate physical disability deteriorated in physical function. Nevertheless, there was a strong link between processing speed and disability after DMT start.
我们分析了 COMparison Between All immunoTherapies for Multiple Sclerosis(NCT03193866),这是一项在瑞典开展的针对复发缓解型多发性硬化症(RRMS)的全国性观察性研究,旨在确定疾病调节治疗(DMT)开始后处理速度和身体残疾的轨迹。
使用群组建模方法,我们评估了 1645 例 RRMS 患者在 2011 年至 2022 年期间首次接受 DMT 治疗后的口服符号数字模态测试(SDMT)处理速度和扩展残疾状态量表(EDSS)的物理残疾轨迹。我们使用群组成员资格作为多项结果来研究轨迹的预测因素,并计算了在轨迹之间链接成员资格的条件概率。
我们确定了 5 种稳定的处理速度轨迹:低 SDMT 分数(平均起始值=29.9;占人口的 5.4%)、低/中(44.3;25.3%)、中(52.6;37.9%)、中/高(63.1;25.8%)和高(72.4;5.6%)。我们确定了 3 种身体残疾轨迹:无残疾/稳定(0.8;26.8%)、轻度残疾/稳定(1.6;58.1%)和中度残疾(3.2;15.1%),这一轨迹会增加到严重残疾。与起始利妥昔单抗的年轻患者相比,起始干扰素的老年患者更有可能处于低处理速度轨迹。与无残疾轨迹相比,起始特立氟胺的老年患者伴有多种合并症和疼痛治疗史更有可能属于中度/重度身体残疾轨迹。处理速度和身体残疾轨迹之间存在很强的关联。
在本队列中,接受积极治疗的 RRMS 患者的处理速度在 DMT 开始后的多年中保持稳定,而中度身体残疾患者的身体功能则恶化。然而,在 DMT 开始后,处理速度与残疾之间存在很强的联系。